LILRB2 Human
HEK293 Cells.
Leukocyte Immunoglobulin-like Receptor, CD85D, CD85d, CD85 antigen-like family member D, CD85d antigen, ILT-4, ILT4, ILT4CD85d, Ig-like transcript 4, Immunoglobulin-like transcript 4, LILRB2, LIR2, LIR-2, LIR2CD85D, Leukocyte immunoglobulin-like receptor 2, MIR10, MIR-10, MIR10LILRA6, Monocyte/macrophage immunoglobulinlike receptor 10, leukocyte immunoglobulin-like receptor subfamily B member 2, leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform 1.
Sterile filtered colorless solution.
Greater than 95.0% as determined by SDS-PAGE.
Description
LILRB2 Human Recombinant produced in HEK293 Cells is a single, glycosylated polypeptide chain containing 444 amino acids (24-461 a.a) and having a molecular mass of 48.3kDa.
LILRB2 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
Leukocyte Immunoglobulin Like Receptor B2 (LILRB2), a member of the leukocyte immunoglobulin-like receptor (LIR) family, is found on immune cells. It binds to MHC class I molecules on antigen-presenting cells and transmits a negative signal, thereby suppressing immune response stimulation. This receptor plays a crucial role in regulating inflammatory responses and cytotoxicity, ensuring a focused immune response and limiting autoreactivity. LILRB2 competes with CD8 alpha for MHC I binding and interacts with both classical MHC I proteins and the non-classical HLA-G1 and HLA-F molecules.
Recombinant human LILRB2, produced in HEK293 cells, is a single, glycosylated polypeptide chain. It comprises 444 amino acids (24-461 a.a), has a molecular weight of 48.3kDa, and includes a 6 amino acid His tag at the C-terminus. Purification is achieved through proprietary chromatographic techniques.
A clear, colorless solution that has been sterilized by filtration.
The LILRB2 solution is provided at a concentration of 0.5mg/ml in phosphate buffered saline (pH 7.4) with 20% glycerol.
For short-term storage (up to 2-4 weeks), keep at 4°C. For longer periods, store frozen at -20°C. Adding a carrier protein (0.1% HSA or BSA) is recommended for long-term storage. Repeated freezing and thawing should be avoided.
Purity is confirmed to be greater than 95.0% using SDS-PAGE analysis.
Leukocyte Immunoglobulin-like Receptor, CD85D, CD85d, CD85 antigen-like family member D, CD85d antigen, ILT-4, ILT4, ILT4CD85d, Ig-like transcript 4, Immunoglobulin-like transcript 4, LILRB2, LIR2, LIR-2, LIR2CD85D, Leukocyte immunoglobulin-like receptor 2, MIR10, MIR-10, MIR10LILRA6, Monocyte/macrophage immunoglobulinlike receptor 10, leukocyte immunoglobulin-like receptor subfamily B member 2, leukocyte immunoglobulin-like receptor subfamily B member 2 soluble isoform 1.
HEK293 Cells.
GTIPKPTLWA EPDSVITQGS PVTLSCQGSL EAQEYRLYRE KKSASWITRI RPELVKNGQF HIPSITWEHT GRYGCQYYSR ARWSELSDPL VLVMTGAYPK PTLSAQPSPV VTSGGRVTLQ CESQVAFGGF ILCKEGEDEH PQCLNSQPHA RGSSRAIFSV GPVSPNRRWS HRCYGYDLNS PYVWSSPSDL LELLVPGVSK KPSLSVQPGP VMAPGESLTL QCVSDVGYDR FVLYKEGERD LRQLPGRQPQ AGLSQANFTL GPVSRSYGGQ YRCYGAHNLS SECSAPSDPL DILITGQIRG TPFISVQPGP TVASGENVTL LCQSWRQFHT FLLTKAGAAD APLRLRSIHE YPKYQAEFPM SPVTSAHAGT YRCYGSLNSD PYLLSHPSEP LELVVSGPSM GSSPPPTGPI STPAGPEDQP LTPTGSDPQS GLGRHLGVHH HHHH
Product Science Overview
Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2), also known as ILT4, is an immunoinhibitory protein expressed on the surface of myeloid cells. This receptor plays a crucial role in regulating immune responses and has garnered significant interest in the field of immuno-oncology due to its potential as a therapeutic target .
LILRB2 is a member of the leukocyte immunoglobulin-like receptor (LILR) family, which includes both activating and inhibitory receptors. LILRB2 contains long cytoplasmic tails with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon activation, these ITIMs recruit SHP protein tyrosine phosphatases, which subsequently impact various cellular processes such as growth, migration, invasion, differentiation, survival, and cellular trafficking .
LILRB2 binds to major histocompatibility complex (MHC) class I molecules, such as HLA-G and HLA-A. This binding inhibits myeloid cell activation and promotes an anti-inflammatory state, often referred to as an M2-like state. This immunosuppressive effect is crucial for maintaining immune homeostasis and preventing excessive inflammation .
Given its role in immune regulation, LILRB2 has been identified as a promising target for cancer immunotherapy. For instance, JTX-8064 is a humanized monoclonal antibody that specifically binds to and antagonizes LILRB2. By blocking LILRB2, JTX-8064 induces a pro-inflammatory, anti-tumor state in macrophages, which can enhance the body’s immune response against tumors .
Research on LILRB2 has primarily focused on its role in cancer and its potential as a therapeutic target. Studies have shown that antagonizing LILRB2 can lead to significant pharmacodynamic responses, including macrophage polarization, interferon-gamma signaling, and T cell inflammation. These findings suggest that targeting LILRB2 could be an effective strategy for enhancing anti-tumor immunity .
